These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 28854283)

  • 1. Transdermal rivastigmine for HIV-associated cognitive impairment: A randomized pilot study.
    Muñoz-Moreno JA; Prats A; Moltó J; Garolera M; Pérez-Álvarez N; Díez-Quevedo C; Miranda C; Fumaz CR; Ferrer MJ; Clotet B;
    PLoS One; 2017; 12(8):e0182547. PubMed ID: 28854283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rivastigmine for HIV-associated neurocognitive disorders: a randomized crossover pilot study.
    Simioni S; Cavassini M; Annoni JM; Métral M; Iglesias K; Rimbault Abraham A; Jilek S; Calmy A; Müller H; Fayet-Mello A; Giacobini E; Hirschel B; Du Pasquier RA
    Neurology; 2013 Feb; 80(6):553-60. PubMed ID: 23345635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A pilot randomized controlled trial evaluating an integrated treatment of rivastigmine transdermal patch and cognitive stimulation in patients with Alzheimer's disease.
    D'Onofrio G; Sancarlo D; Addante F; Ciccone F; Cascavilla L; Paris F; Elia AC; Nuzzaci C; Picoco M; Greco A; Panza F; Pilotto A
    Int J Geriatr Psychiatry; 2015 Sep; 30(9):965-75. PubMed ID: 25504466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rivastigmine for mild cognitive impairment in Parkinson disease: a placebo-controlled study.
    Mamikonyan E; Xie SX; Melvin E; Weintraub D
    Mov Disord; 2015 Jun; 30(7):912-8. PubMed ID: 25914281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and tolerability of rivastigmine patch therapy in patients with mild-to-moderate Alzheimer's dementia associated with minimal and moderate ischemic white matter hyperintensities: A multicenter prospective open-label clinical trial.
    Park KW; Kim EJ; Han HJ; Shim YS; Kwon JC; Ku BD; Park KH; Yi HA; Kim KK; Yang DW; Lee HW; Kang H; Kwon OD; Kim S; Lee JH; Chung EJ; Park SW; Park MY; Yoon B; Kim BC; Seo SW; Choi SH
    PLoS One; 2017; 12(8):e0182123. PubMed ID: 28786987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selegiline transdermal system (STS) for HIV-associated cognitive impairment: open-label report of ACTG 5090.
    Evans SR; Yeh TM; Sacktor N; Clifford DB; Simpson D; Miller EN; Ellis RJ; Valcour V; Marra CM; Millar L; Schifitto G;
    HIV Clin Trials; 2007; 8(6):437-46. PubMed ID: 18042509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial.
    Farlow M; Potkin S; Koumaras B; Veach J; Mirski D
    Arch Neurol; 2003 Jun; 60(6):843-8. PubMed ID: 12810489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multicenter trial of selegiline transdermal system for HIV-associated cognitive impairment.
    Schifitto G; Zhang J; Evans SR; Sacktor N; Simpson D; Millar LL; Hung VL; Miller EN; Smith E; Ellis RJ; Valcour V; Singer E; Marra CM; Kolson D; Weihe J; Remmel R; Katzenstein D; Clifford DB;
    Neurology; 2007 Sep; 69(13):1314-21. PubMed ID: 17652642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rivastigmine Transdermal Patch Treatment for Moderate to Severe Cognitive Impairment in Veterans with Traumatic Brain Injury (RiVET Study): A Randomized Clinical Trial.
    Brawman-Mintzer O; Tang XC; Bizien M; Harvey PD; Horner MD; Arciniegas DB; Raskind M; Johnson-Greene L; Martineau RJ; Hamner M; Rodriguez-Suarez M; Jorge RE; McGarity S; Wortzel HS; Wei Y; Sindowski T; Mintzer J; Kindy AZ; Donovan K; Reda D
    J Neurotrauma; 2021 Jul; 38(14):1943-1952. PubMed ID: 33514274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Efficacy of Transdermal Rivastigmine in Mild to Moderate Alzheimer's Disease with Concomitant Small Vessel Cerebrovascular Disease: Findings from an Open-Label Study.
    Yatawara C; Zailan FZ; Chua EV; Lim LLH; Silva E; Wang JS; Ng A; Ng KP; Kandiah N
    Clin Interv Aging; 2021; 16():301-309. PubMed ID: 33642856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurocognitive impairment in treatment-experienced adults living with HIV attending primary care clinics in Zimbabwe.
    Nyamayaro P; Gouse H; Hakim J; Robbins RN; Chibanda D
    BMC Infect Dis; 2020 May; 20(1):383. PubMed ID: 32471350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer's disease: a post hoc analysis.
    Farlow MR; Alva G; Meng X; Olin JT
    Curr Med Res Opin; 2010 Feb; 26(2):263-9. PubMed ID: 19929593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tolerability and efficacy of memantine add-on therapy to rivastigmine transdermal patches in mild to moderate Alzheimer's disease: a multicenter, randomized, open-label, parallel-group study.
    Choi SH; Park KW; Na DL; Han HJ; Kim EJ; Shim YS; Lee JH;
    Curr Med Res Opin; 2011 Jul; 27(7):1375-83. PubMed ID: 21561398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lithium improves HIV-associated neurocognitive impairment.
    Letendre SL; Woods SP; Ellis RJ; Atkinson JH; Masliah E; van den Brande G; Durelle J; Grant I; Everall I;
    AIDS; 2006 Sep; 20(14):1885-8. PubMed ID: 16954730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Memantine and HIV-associated cognitive impairment: a neuropsychological and proton magnetic resonance spectroscopy study.
    Schifitto G; Navia BA; Yiannoutsos CT; Marra CM; Chang L; Ernst T; Jarvik JG; Miller EN; Singer EJ; Ellis RJ; Kolson DL; Simpson D; Nath A; Berger J; Shriver SL; Millar LL; Colquhoun D; Lenkinski R; Gonzalez RG; Lipton SA; ; ;
    AIDS; 2007 Sep; 21(14):1877-86. PubMed ID: 17721095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of switching to the rivastigmine transdermal patch from oral cholinesterase inhibitors: a naturalistic prospective study in Alzheimer's disease.
    Cagnin A; Cester A; Costa B; Ermani M; Gabelli C; Gambina G;
    Neurol Sci; 2015 Mar; 36(3):457-63. PubMed ID: 25394739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-life effectiveness and tolerability of the rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer's disease: the EMBRACE study.
    Gauthier S; Robillard A; Cohen S; Black S; Sampalis J; Colizza D; de Takacsy F; Schecter R;
    Curr Med Res Opin; 2013 Aug; 29(8):989-1000. PubMed ID: 23647369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term effects of rivastigmine capsules in patients with traumatic brain injury.
    Silver JM; Koumaras B; Meng X; Potkin SG; Reyes PF; Harvey PD; Katz DI; Gunay I; Arciniegas DB
    Brain Inj; 2009 Feb; 23(2):123-32. PubMed ID: 19191091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term effects of rivastigmine treatment on neuropsychiatric and behavioral disturbances in nursing home residents with moderate to severe Alzheimer's disease: results of a 52-week open-label study.
    Aupperle PM; Koumaras B; Chen M; Rabinowicz A; Mirski D
    Curr Med Res Opin; 2004 Oct; 20(10):1605-12. PubMed ID: 15462693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized controlled trial of rivastigmine in patients with cognitive impairment no dementia because of cerebrovascular disease.
    Narasimhalu K; Effendy S; Sim CH; Lee JM; Chen I; Hia SB; Xue HL; Corrales MP; Chang HM; Wong MC; Chen CP; Tan EK
    Acta Neurol Scand; 2010 Apr; 121(4):217-24. PubMed ID: 19951274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.